The importance of human chorionic gonadotropin support of the corpus luteum during human gonadotropin therapy in women with anovulatory infertility.
One hundred ten women with anovulatory infertility (World Health Organization [WHO] group I n = 50, WHO group II n = 60) were given 341 treatment courses with human menopausal gonadotropin (hMG) and human chorionic gonadotropin (hCG). Additional hCG was given as single or repeated injections during the luteal phase in 205 ovulatory cycles. In WHO group I, the incidence of luteal phase defects was lower and the pregnancy rate higher in cycles with extra hCG administration during the luteal phase than in cycles with no extra hCG. In WHO group II, there was no such difference after supplemental hCG. The abortion rate was the same after cycles with or without extra hCG administration. It is suggested that during ovulation induction with hMG/hCG in anovulatory women with no evidence of endogenous estrogen activity, the luteal phase should be supplemented with additional hCG.
D000328:Adult; D000858:Anovulation / Q000188:drug therapy* / Q000503:physiopathology; D006063:Chorionic Gonadotropin / Q000494:pharmacology / Q000627:therapeutic use*; D003338:Corpus Luteum / Q000187:drug effects / Q000502:physiology; D005260:Female; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy* / Q000503:physiopathology; D008596:Menotropins / Q000494:pharmacology / Q000627:therapeutic use*; D011247:Pregnancy / Q000187:drug effects
D006063:Chorionic Gonadotropin; D008596:Menotropins